Amgen (NASDAQ:AMGN) Earns Outperform Rating from Royal Bank of Canada
Amgen (NASDAQ:AMGN – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank of Canada in a report issued on Friday,Benzinga reports. They currently have a $324.00 price target on the medical research company’s stock. Royal Bank of Canada’s target price points to a potential upside of 17.56% from the […]
More Stories
Trump Floats Taxpayer-Funded Takeover of Spirit Airlines, Selling for Profit
By Chris Summers President Donald Trump said on April 23 that a taxpayer-funded takeover of Spirit Airlines could be an...
Release Date for The Wonderfools Announced! Cast, Character, and Trailer
Netflix’s upcoming supernatural and comedy Korean drama, The Wonderfools, is ready to premiere soon. Kang Eun-kyung, known for series like...
United Airlines Says Ticket Prices May Rise by up to 20 Percent to Offset Jet Fuel Surge
By Guy Birchall United Airlines may have to raise ticket prices by up to 20 percent to offset the spike...
Trump Says Iran Is Without a Leader, ‘Infighting’ Creating Confusion
By Jack Phillips U.S. President Donald Trump said he believes the Iranian regime is effectively without a leader and is...
Treasury Sanctions International Drug Network Tied to Sinaloa Cartel
By Andrew Moran The Treasury Department has introduced sanctions on 23 individuals and organizations involved in a sophisticated synthetic‑opioid procurement...
US Government to Implement New Credit Score Models for Mortgages
By Naveen Athrappully The Federal Housing Administration (FHA) has joined with Fannie Mae and Freddie Mac to implement new mortgage...